JP2023509215A5 - - Google Patents

Info

Publication number
JP2023509215A5
JP2023509215A5 JP2022542269A JP2022542269A JP2023509215A5 JP 2023509215 A5 JP2023509215 A5 JP 2023509215A5 JP 2022542269 A JP2022542269 A JP 2022542269A JP 2022542269 A JP2022542269 A JP 2022542269A JP 2023509215 A5 JP2023509215 A5 JP 2023509215A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
chain variable
heavy chain
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022542269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/070907 external-priority patent/WO2021139780A1/en
Publication of JP2023509215A publication Critical patent/JP2023509215A/ja
Publication of JP2023509215A5 publication Critical patent/JP2023509215A5/ja
Ceased legal-status Critical Current

Links

JP2022542269A 2020-01-10 2021-01-08 抗tigit抗体、それを含む多重特異性抗体及びその使用方法。 Ceased JP2023509215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020071336 2020-01-10
CNPCT/CN2020/071336 2020-01-10
PCT/CN2021/070907 WO2021139780A1 (en) 2020-01-10 2021-01-08 Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same

Publications (2)

Publication Number Publication Date
JP2023509215A JP2023509215A (ja) 2023-03-07
JP2023509215A5 true JP2023509215A5 (cg-RX-API-DMAC7.html) 2024-01-16

Family

ID=76787751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542269A Ceased JP2023509215A (ja) 2020-01-10 2021-01-08 抗tigit抗体、それを含む多重特異性抗体及びその使用方法。

Country Status (10)

Country Link
US (1) US20230060388A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087877A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023509215A (cg-RX-API-DMAC7.html)
KR (1) KR20220131261A (cg-RX-API-DMAC7.html)
CN (1) CN115023442A (cg-RX-API-DMAC7.html)
AU (1) AU2021206421A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013403A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021139780A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208799B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
WO2023064909A1 (en) * 2021-10-14 2023-04-20 Nighthawk Biosciences, Inc. Bifunctional anti-pathogenic agents
TW202417512A (zh) * 2022-10-17 2024-05-01 英屬開曼群島商百濟神州有限公司 含有抗tigit抗體的配製物及其使用方法
CN118420712A (zh) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 一种三特异性抗体技术平台及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
SI4339615T1 (sl) * 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス,インコーポレーテッド 多重特異性分子及びその使用
SG11202004158QA (en) * 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
CN110818795B (zh) * 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法

Similar Documents

Publication Publication Date Title
JP2023509214A5 (cg-RX-API-DMAC7.html)
JP2023509196A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2015509947A5 (cg-RX-API-DMAC7.html)
JP2024515536A5 (cg-RX-API-DMAC7.html)
JP2022516881A5 (cg-RX-API-DMAC7.html)
JP2022516503A5 (cg-RX-API-DMAC7.html)
JP2016536020A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2015509948A5 (cg-RX-API-DMAC7.html)
JP2024520188A5 (cg-RX-API-DMAC7.html)
JP2010524435A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2024511137A5 (cg-RX-API-DMAC7.html)
JP2016011306A (ja) ヒト化axl抗体
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2023037000A5 (cg-RX-API-DMAC7.html)
JP2022513729A5 (cg-RX-API-DMAC7.html)
JP2025503229A5 (cg-RX-API-DMAC7.html)